In the latest trading session, 0.52 million BioAtla Inc (NASDAQ:BCAB) shares changed hands as the company’s beta touched 1.09. With the company’s most recent per share price at $0.72 changing hands around $0.03 or 3.29% at last look, the market valuation stands at $20.11M. BCAB’s current price is a discount, trading about -458.33% off its 52-week high of $4.02. The share price had its 52-week low at $0.67, which suggests the last value was 6.94% up since then. When we look at BioAtla Inc’s average trading volume, we note the 10-day average is 1.21 million shares, with the 3-month average coming to 1.30 million.
Analysts gave the BioAtla Inc (BCAB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BCAB as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. BioAtla Inc’s EPS for the current quarter is expected to be -0.34.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BioAtla Inc (NASDAQ:BCAB) trade information
Instantly BCAB is in green as seen in intraday trades today. With action -47.03%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -70.93%, with the 5-day performance at -47.03% in the red. However, in the 30-day time frame, BioAtla Inc (NASDAQ:BCAB) is -48.55% down. Looking at the short shares, we see there were 3.98 million shares sold at short interest cover period of 3.7 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 85.6% from its recent market value. According to analyst projections, BCAB’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -594.44% plunge from its current level, while the stock would need to soar -594.44% for it to hit the projected low.
BioAtla Inc (BCAB) estimates and forecasts
Data shows that the BioAtla Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -53.26% over the past 6 months, a 42.25% in annual growth rate that is considerably higher than the industry average of 17.20%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -25.30%. The 2024 estimates are for BioAtla Inc earnings to increase by 40.93%.
BCAB Dividends
BioAtla Inc is expected to release its next quarterly earnings report in January.
BioAtla Inc (NASDAQ:BCAB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 10.75% of BioAtla Inc shares while 42.79% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 47.95%. There are 42.79% institutions holding the BioAtla Inc stock share, with SOLEUS CAPITAL MANAGEMENT, L.P. the top institutional holder. As of 2024-06-30, the company held 8.113% of the shares, roughly 3.9 million BCAB shares worth $5.34 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 3.9205% or 1.89 million shares worth $2.58 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 1.27 shares estimated at $0.9 million under it, the former controlled 2.63% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 1.14% of the shares, roughly 549.45 shares worth around $0.39 million.
